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Introduction
Prostate cancer (PCa) is the second most frequently diagnosed cancer in developed countries and the third most common cause of death from cancer in men [1] . Early detection of PCa allows for curative therapies such as castration and radiation treatments. However, despite the emergence of new treatments, advanced disease represents a challenge to treat with no effective treatment options available [2] . Androgens play an important role during all phases of PCa growth through activation of the androgen receptor (AR) in epithelial and stromal cells [3] . The standard therapy for patients with advanced PCa is androgen ablation by surgical or medical castration. However, following initial remission, the majority of tumours eventually relapse, predominantly within the bone. These tumours are termed castration-resistant PCa (CRPC). More than 80% of all men who die of PCa have metastatic disease located within the bone [4] , the majority of which are patients with CRPC. The mechanisms controlling CRPC growth in bone metastases are largely unknown and scantly explored by actually examining such bone metastases in patients.
The serum response factor (SRF) is a widely expressed transcription factor involved in cellular proliferation and cytoskeletal organisation as well as cellular growth, differentiation and resistance to apoptosis [5, 6] . Known SRF target genes are characterised by single or multiple copies of the serum responsive elements (SRE) which contain the consensus sequence CC [A/T] 2 A[A/T] 3 GG, generally known as CArG box [7] . SRF has been recently associated with PCa development and progression. SRF was firstly shown to play a role in PCa by Heemers and colleagues [8] who demonstrated that it is an important determinant of AR action through the transcriptional activation of four and a half LIM domain protein 2 (FHL2) which is up-regulated in PCa and associated with poor prognosis. In addition, inhibition of SRF has been shown to impact cellular proliferation in PCa cell lines by our group and others [2, 8] . SRF protein expression in PCa tissues has been investigated by Yu et al. [9] who performed immunohistochemistry on more than 400 PCa samples from radical prostatectomies.
In this study, SRF expression correlated significantly with both extracapsular extension and Gleason score as well as with proliferation, while negatively correlating with apoptosis. SRF association with Gleason score has been confirmed by our group. In addition we have demonstrated that SRF is associated with castration-resistance in CRPC transurethral resections of the prostate (TURPS) [2] .
The aim of this study was to evaluate SRF protein expression in PCa metastases.
Materials and Methods

Sample Collection/Tissue Microarray Construction
Human tissue microarrays were constructed consisting of 65 soft tissue metastases and 120 bone metastases from 42 patients with advanced PCa. Samples were obtained from patients who died of metastatic CRPC and who signed written informed consent for a rapid autopsy to be performed ideally within 2 hours of death, under the aegis of the Prostate Cancer Donor Program at the University of Washington [10] . Two replicate 1 mm cores of soft tissue metastases and bone metastases were taken from every case where available [11] . The tissue microarrays were assembled using the Beecher Instruments Tissue-Arrayer TM (Beecher Instruments, Silver Spring, MD).
Immunohistochemical (IHC) Analysis
Immunohistochemical staining for SRF was performed using a microwave-induced antigen retrieval method. De-waxed sections were immersed in a citric acid buffer (0.01M, pH 6.0), placed in a 700W microwave oven at full power for 15 min. Using a standard avidin-biotin complex method (Vector Laboratories, Inc.), the sections were incubated with polyclonal rabbit (Santa Cruz Biotechnology, Inc.
-1:800 dilution) at 4ºC overnight. The colour reaction product was obtained with DAB and counterstained with Haematoxylin. Tonsil sections were used as positive controls. Prior to this study, the SRF antibody was subjected to western blot analysis using LNCaP cell lines which confirmed specificity for SRF (data not shown ) [2] .
Scoring of SRF Protein Expression and Statistical Analysis
Some unusable cores were found in the TMAs due to the tissue cores being missing, cancer necrosis, or insufficient cancer cells. These cores were excluded from the study. Nuclear immunoreactivity for SRF was assessed in soft tissue metastases and bone metastases by two independent observers 
Results
SRF expression in PCa Metastatic Tissue
Heterogeneous expression of SRF was observed in individual patients
Of the 42 patients ( Figure 2 ), 11 showed (26.19%) no SRF nuclear expression in any metastatic site, 
SRF expression in PCa Metastatic Tissue correlates with survival
Only 38 patients were included in the survival analysis from diagnosis with CRPC, since this information was not available for 4 patients. Rank test, p=0.020) ( Figure 5 ) and [b] diagnosis with CRPC (Log Rank test, p=0.043) ( Figure 6 ).
Finally, a multivariate analysis was carried out to measure the ability of SRF to predict survival. This showed that SRF is a significant predictor of survival from [a] PCa diagnosis (p=0.012) ( 
Discussion
The immunohistochemical evaluation of SRF in PCa metastatic clinical samples has not previously been reported. In this study, we evaluated the tissue expression profile of SRF in 151 metastatic sites from 42 patients who died of advanced PCa. These metastatic sites consisted of both bone metastases and soft tissue metastases from each patient. It has previously been reported by our group and others that SRF nuclear positivity was associated with higher Gleason score in primary PCa tissues [9] and castrate-resistant TURPs [2] suggesting that SRF may play a role in PCa progression. In addition, we recently showed an association between changes between the original tumour and its metastases. Therefore, when metastatic cells progress from the primary tumour, biological heterogeneity is found within a single metastasis and among different metastases [12] . This may explain the unexpected disparity in the level of SRF expression observed in castrate-resistant primary tumour versus castrate-resistant metastatic tumour in our studies. Moreover, abundant literature has shown genetic and epigenetic heterogeneity at different metastatic sites, accounting for the phenotypic heterogeneity in prostate cancer metastases. Previous studies have shown a plethora of heterogeneous molecular aberrations in prostate cancer metastases including variable expression of the androgen receptor [11] , interfocal heterogeneity of PTEN/MMAC1 gene alterations [13] , differential extent of neuroendocrine differentiation [10] , significantly higher Ecadherin expression in bone metastases compared with lymph node and soft tissue metastases [14] and different cell survival mechanisms in bone and soft tissue metastases, which rely on differential expression of survival proteins [15] . In addition, epigenetic mechanisms which are responsible for deregulating key oncogenes and onco-suppressor genes are also involved in the heterogeneity of prostate cancer metastases, as shown by Yegnasubramanian and colleagues [16] , who demonstrated that DNA hypomethylation patterns are quite heterogeneous across different metastatic sites within the same patient.
Although an association between SRF positivity and PCa metastases was not shown in the current study, a significant negative correlation between SRF expression in bone metastases and survival from [a] diagnosis with PCa and [b] diagnosis with CRPC was found. Moreover, univariate Cox proportional hazards modelling showed that only SRF is a significant predictor of survival from PCa and CRPC diagnosis. It should also be noted that only Gleason score 9 was found to be a significant predictor of survival from PCa diagnosis but not for CRPC diagnosis, suggesting that SRF is an independent predictor from Gleason score. These findings are in line with a previous study which showed an association between SRF expression in primary PCa tissues and poor outcome following radical prostatectomy [9] . This data also suggest that SRF plays a key role in CRPC metastases in 
